Molecular Testing Episodes

If your thyroid biopsy came back indeterminate — Bethesda 3 or 4 — you may have been told surgery is your only option. For decades, over 70% of those surgeries revealed tissue that was actually benign. There is a better way. It's called molecular testing. And today's guest helped prove it works. Dr. Joshua Klopper is the Medical Director for Endocrinology at Veracyte and was an investigator on the original clinical study that validated the Afirma Genomic Sequencing Classifier. He served on the board of the American Thyroid Association and spent over two decades managing thyroid nodules and thyroid cancer. Disclosure: Dr. Klopper is an employee of Veracyte, maker of the Afirma test discussed in this episode. In this episode Dr. Klopper breaks down everything a thyroid patient needs to know about molecular testing in plain language. Why the test was designed to find benign tissue rather than cancer. What a benign result actually means. Why a suspicious result doesn't automatically m…

Today’s guest is Dr. Oliver Bathe, the CEO and founder of Qualisure Diagnostics. Dr. Bathe is a surgical oncologist with over 25 years of clinical experience. As a result, he has an excellent understanding of the challenges that patients and clinicians face during their cancer Journey. He has been involved in research that applies cutting edge technological solutions to real clinical problems. In recent years, Dr. Bathe founded Qualisure Diagnostics, a company that develops molecular tests that ...